EGFR-TKI-RESISTANT NON-SMALL CELL LUNG CANCER
Clinical trials for EGFR-TKI-RESISTANT NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new EGFR-TKI-RESISTANT NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for EGFR-TKI-RESISTANT NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New PET scan could predict who benefits from targeted lung cancer therapy
Disease control Not yet recruitingThis study investigates a drug called sacituzumab govitecan, which targets the TROP2 protein, in people with advanced non-small cell lung cancer that has stopped responding to standard EGFR-targeted treatments. Researchers are also comparing two types of PET/CT scans—one standard…
Matched conditions: EGFR-TKI-RESISTANT NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Zhou Chengzhi • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Can immune cells revive lung cancer treatment?
Disease control Not yet recruitingThis early-phase trial tests whether combining a patient's own immune cells (called TILs) with a targeted therapy drug can safely treat advanced lung cancer that has stopped responding to standard targeted treatment. Researchers will enroll 50 adults with EGFR-mutant non-small ce…
Matched conditions: EGFR-TKI-RESISTANT NON-SMALL CELL LUNG CANCER
Phase: EARLY_PHASE1 • Sponsor: Tianjin Medical University General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC